Home
This site is intended for healthcare professionals
Sign upLog in

Key Clinical Summary: Rethink Pulmonary Arterial Hypertension - Optimize Escalation and Combination Therapy

This is a micro-learning module summary of a presentation by Dr. Sudarshan Rajagopal, which you can find here. Before participating, please read our CME and disclosure information which can be found here.

This program is supported by an independent educational grant from MSD. This online education program is designed solely for healthcare professionals in the USA. The content is not available for HCPs in any other country.

Myth 3: Feeling Better is Stable

Introduction
This summary examines contemporary strategies for treatment escalation in pulmonary arterial hypertension (PAH), emphasizing the limitations of relying on subjective symptomatic improvement, the role of structured risk assessment, and the expanding therapeutic landscape. It outlines key principles of modern PAH management and current guideline‑directed approaches to intensification, including optimization of prostacyclin therapy, evaluation of modifiable contributors, and the integration of emerging agents such as sotatercept.

Initial Presentation and Clinical Context

  • A young woman with obesity (body mass index [BMI] 45 kg/m2) and history of stimulant use presented for reassessment of idiopathic PAH
  • Initial diagnosis occurred 3 years earlier, with dual oral therapy started upfront
  • Symptomatic improvement on two agents was modest and insufficient to achieve low‑risk status
  • Subcutaneous treprostinil was added after 6 months, titrated to 20 ng/kg/min at the time of reassessment
  • Despite feeling better, she remained functionally limited and concerned about long‑term prognosis

Risk Assessment and Prognostic Implications

  • Follow‑up evaluation incorporated the REVEAL Lite 2 risk calculator, which includes functional class; six‑minute walk distance (6MWD); NT‑proBNP or BNP; systolic blood pressure (SBP); heart rate (HR); and renal function
  • Her REVEAL Lite 2 score was 6, placing her in the low–intermediate risk category
  • Key findings:
    • Functional class (FC) II
    • 6MWD 377 m
    • NT‑proBNP 325 pg/mL
    • SBP 101 mmHg, HR 92 bpm
    • Normal renal function
  • Survival data from contemporary registries demonstrate:
    • Low–intermediate risk is associated with >95% 1‑year survival, but a steep decline over time, with up to 40% mortality rate at 5 years
    • Only patients achieving and maintaining low‑risk status demonstrate favorable long‑term outcomes
  • These data reinforce that subjective improvement does not equate to clinical stability and should not delay treatment escalation

Hemodynamic and Echocardiographic Evaluation

  • Mean pulmonary artery pressure (PAP) improved from 53 to 45 mmHg
  • Cardiac index remained borderline at 2.3 L/min/m²
  • Pulmonary vascular resistance (PVR) decreased from 8.2 to 6.3 WU
  • Mild right atrial and right ventricular enlargement
  • Septal flattening consistent with pressure overload
  • No overt signs of advanced right‑sided failure
  • Persistent hemodynamic abnormalities supported the need for further intensification, despite symptomatic gains

Treatment Options in 2023

  • Management aligned with guideline‑directed escalation for patients not achieving low‑risk status
  • Key interventions included:
    • Up‑titration of subcutaneous treprostinil: Increased from 20 to 63 ng/kg/min over the following year, with monitoring for excessive cardiac output and tolerability
    • Evaluation for non‑PAH contributors: Overnight oximetry, complete blood count, basic metabolic panel and thyroid-stimulating hormone all unremarkable
    • Weight optimization: Referral to a weight‑wellness program and initiation of semaglutide therapy
      • BMI reduced from 45 to 29.6, improving symptoms and potential transplant eligibility
    • Pulmonary rehabilitation: To improve functional capacity and exercise tolerance

Evolving Treatment Options (2024–2025)

  • Despite optimized triple therapy, follow‑up assessment in 2024 showed continued low–intermediate risk
  • Contemporary treatment algorithms (7th World Symposium on Pulmonary Hypertension) support additional escalation in such patients
  • Available options included:
    • Addition of sotatercept, an activin signaling inhibitor
    • Switch from phosphodiesterase 5 inhibitor (PDE5i) to riociguat, though limited by low blood pressure in this case
    • Further prostacyclin intensification, if not already maximized
  • Sotatercept was selected based on demonstrated improvements in 6MWD (STELLAR trial); reductions in clinical worsening (ZENITH, HYPERION trials); and benefits across multiple clinical and hemodynamic endpoints

Outcomes Following Four‑Drug Therapy

  • By 2025, the patient was receiving a PDE5i, an endothelin receptor antagonist, subcutaneous treprostinil, and sotatercept
  • Improvements included:
    • 6MWD increased to 488 m
    • NT‑proBNP decreased to 58 pg/mL
    • Persistent FC II but with markedly improved biomarkers
    • Mean PAP decreased to 32 mmHg
    • Cardiac index increased to 3.1 L/min/m²
    • PVR decreased to 4.5 WU
  • These findings illustrate the potential for substantial recovery of cardiopulmonary function with timely, aggressive, guideline‑directed escalation

Conclusions
This case underscores that subjective symptomatic improvement in PAH does not reliably indicate clinical stability. Structured risk assessment remains essential, as low–intermediate risk carries a significant long‑term mortality risk. Modern management requires early escalation to achieve low‑risk status, including optimization of prostacyclin therapy, evaluation of modifiable contributors, and incorporation of emerging agents such as sotatercept. Maximal medical therapy now commonly includes four‑drug regimens, reflecting an evolving paradigm aimed at improving long‑term outcomes in this life‑threatening disease.

Content is accurate as of the date of release on 13 February 2026.